In JIA, the incidence of serious infections during anti-TNF-α therapy ranges from approximately 2 to 5 per 100 patient-years, while the risk of malignancy appears to be very low, with large registries not showing a clear increase compared to the general pediatric population. The gene discussed is TNF; the disease is infection.